Key Points
Lawrence Erik Kurzius, a Director at Elanco Animal Health(NYSE:ELAN), acquired 40,000 shares of common stock at $23.40 per share on August 20, 2026, according to a recently filed SEC Form 4.
Transaction Summary
MetricValueTransaction value$936,000Shares purchased40,000Post-transaction shares (directly held)188,647Post-transaction value$4.4 million
Transaction value based on SEC Form 4 weighted average purchase price ($23.40); post-transaction value based on Aug. 20, 2026, market close ($23.56).
Key Questions
- How significant is this purchase relative to the insider’s existing position?
This acquisition of 40,000 shares represents a 27% expansion of the insider’s direct holdings, increasing the total stake from 148,647 shares to 188,647 shares. - What were the specific execution details of this trade?
The purchase was executed at a weighted average price of $23.40 per share, with individual transaction prices ranging from $23.385 to $23.40 on Aug. 20, 2026. - What is the current scale of the company’s operations?
Elanco, an animal health company based in Indianapolis, maintains a market capitalization of $12.2 billion and generated $5 billion in trailing twelve-month revenue as of the Aug. 20, 2026, market close. - Does the insider hold other forms of equity in the firm?
Beneficial ownership is held exclusively through direct holdings, which total 188,647 shares, as the reporting person does not maintain any indirect positions in the issuer.
Company Overview
MetricValueShare Price (as of market close 2026-08-20)$23.56Market Capitalization$11.8 billionRevenue (TTM)$5 billionNet Income (TTM)-$199 million
Company Snapshot
- Elanco Animal Health develops, manufactures, and commercializes a comprehensive portfolio of animal health solutions for both companion animals and livestock, including preventative parasiticides, vaccinations, and therapeutic treatments under recognized brands such as Seresto, Advantage, Advantix, and Advocate.
- The company generates revenue through the sale of pharmaceutical and health products for companion animals and livestock producers, leveraging a diversified product portfolio that addresses both preventative and therapeutic animal health needs across multiple market segments.
- Elanco serves veterinarians, pet owners, livestock producers, and agricultural operations globally, positioning itself as a comprehensive provider of animal health solutions across companion animal and production animal markets.
Elanco Animal Health is a leading global animal health company with approximately 9,400 employees and TTM revenues of $5 billion, demonstrating substantial scale in the specialized pharmaceutical and animal health sector. The company maintains a diversified business model spanning companion animal preventative care, therapeutic treatments, and livestock health solutions, enabling revenue generation across multiple customer segments and geographies. Elanco’s competitive positioning is strengthened by its portfolio of established brands and comprehensive product offerings that address critical animal health needs in both companion and production animal markets.
What This Transaction Means for Investors
The recent share purchase by Kurzius serves as a bullish signal to shareholders regarding the company’s potential direction. Elanco’s stock price has climbed 40% over the past 12 months, while the S&P 500 is up 18.7% over the same period. Given this strong performance, it would have been understandable if the executive had decided to take some profits off the table. Instead, this purchase demonstrates that Kurzius not only wants to retain his existing shares but is committed to expanding his position. The size of the acquisition represents a substantial increase to his overall holdings.
Alongside Kurzius, market analysts also appear optimistic about the stock. According to CNN, of the 18 analysts covering Elanco, 89% rate it a buy, while only 11% rate it a hold. The stock has no sell ratings from that group. The median 12-month price target from this group is $32, representing a potential gain of 31.3% from the current price. The group’s highest target stands at $34, suggesting a potential gain of nearly 40%, while the lowest price target is $26, which would still represent a 6.7% gain. The combination of insider buying and favorable analyst price targets provides two bullish indicators for shareholders regarding what may lie ahead in the near term.
Jack Delaney has no position in any of the stocks mentioned.
